GSK, Theravance race rivals with PhIII COPD data on LAMA/LABA combo

GlaxoSmithKline ($GSK) and Theravance ($THRX) have rolled out a battery of data from a slate of late-stage studies of their LAMA/LABA combo for COPD. And the partners say the numbers will back up thei…
Read the full story: News